Novo ' s Insulin/GLP-1 Agonist Combo IDegLira Delayed in US Novo ' s Insulin/GLP-1 Agonist Combo IDegLira Delayed in US

IDegLira, the Novo Nordisk injectable combination of insulin degludec and liraglutide, has received a setback in the United States where the FDA says it needs 3 more months to consider approval.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news